Enhanced Water-Soluble Cannabinoid and/or Terpene Extracts with Improved Bioavailability and Adjustable Bulk Density

Publication ID: 24-11857589_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Water-Soluble Cannabinoid and/or Terpene Extracts with Improved Bioavailability and Adjustable Bulk Density,” Published Technical Disclosure No. 24-11857589_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857589_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,589.

Summary of the Inventive Concept

The present inventive concept relates to a system, method, and composition for preparing and manufacturing water-soluble, powdered cannabinoid and/or terpene extracts with enhanced bioavailability and adjustable bulk density, overcoming the limitations of existing extraction methods.

Background and Problem Solved

The original patent disclosed a water-soluble, powdered cannabinoid and/or terpene extract, but it had limitations in terms of bioavailability and bulk density adjustability. The present inventive concept addresses these limitations by introducing a combination of emulsifiers to enhance bioavailability and a novel manufacturing process to achieve adjustable bulk density.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for preparing a water-soluble, powdered cannabinoid and/or terpene extract, involving a solvent and a combination of emulsifiers selected to enhance bioavailability. The method involves mixing the extract with the solvent and emulsifiers, followed by spray-drying to form a powder. The resulting powder has an adjustable bulk density based on the final dosage form desired. The composition further comprises a pH-dependent release agent and is loaded onto a mesoporous silica.

Novelty and Inventive Step

The new claims introduce a novel combination of emulsifiers to enhance bioavailability, a manufacturing process that achieves adjustable bulk density, and a pH-dependent release agent, which are not present in the original patent. These features provide a non-obvious improvement over the existing extraction methods.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include using different types of emulsifiers, solvents, or release agents. Variations may also include different manufacturing processes, such as freeze-drying or granulation, to achieve the desired bulk density and bioavailability.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the pharmaceutical and nutraceutical industries, particularly in the development of cannabis-based products with improved bioavailability and adjustable dosage forms. The target market includes manufacturers of cannabis-based products, pharmaceutical companies, and research institutions.

CPC Classifications

SectionClassGroup
A A61 A61K36/185
A A61 A61K9/107
A A61 A61K47/02
A A61 A61K47/36
A A61 A61K47/40
A A61 A61K47/44

Field of Art

Pharmaceutical cannabinoid extraction and formulation technologies, with expertise in solvent extraction, emulsification, powder processing, and drug delivery systems for botanical compounds

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences, chemical engineering, or related fields, possessing knowledge of extraction techniques, emulsification processes, and drug formulation strategies for botanical compounds

Obviousness Rationale

A PHOSITA would recognize that the PTD represents predictable variations on the source patent's core cannabinoid extraction methodology, utilizing standard pharmaceutical engineering techniques to incrementally improve extract solubility, bioavailability, and processing flexibility. The disclosed modifications represent routine optimization of known extraction and formulation strategies within the cannabinoid pharmaceutical domain. The technical variations demonstrate expected engineering adaptations that would be apparent to a skilled practitioner seeking to enhance cannabinoid extract performance.

Obvious Combinations & Variations

Source Patent Element
Water-soluble micronized cannabis extract complexed with cyclodextrin
PTD Variation
Adding pH-dependent release agent and alternative emulsification combinations
Obviousness Reasoning
Modifying release characteristics and emulsification is a predictable design choice for improving pharmaceutical extract performance, using known pharmaceutical engineering techniques
Source Patent Element
Mesoporous silica loading technique for extract stabilization
PTD Variation
Introducing alternative spray-drying and loading processes to adjust bulk density
Obviousness Reasoning
Adjusting powder processing parameters represents a standard engineering approach to modifying material properties, utilizing well-established pharmaceutical formulation techniques
Source Patent Element
Cannabinoid extract with maltodextrin and acacia emulsification
PTD Variation
Exploring additional emulsifier combinations to enhance bioavailability
Obviousness Reasoning
Systematic exploration of emulsification strategies is an expected method of incremental pharmaceutical innovation, representing a finite set of predictable modifications
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this published technical disclosure would have been obvious to a person having ordinary skill in the art at the time of invention, as the technical modifications represent predictable extensions of the foundational extraction methodology disclosed in US Patent 11857589, utilizing standard pharmaceutical engineering techniques to incrementally improve cannabinoid extract formulation and processing characteristics.

Original Patent Information

Patent NumberUS 11,857,589
TitleWater-soluble, powdered cannabinoid and/or terpene extract
Assignee(s)MEDPHARM HOLDINGS, LLC